| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442101 | European Journal of Cancer | 2015 | 12 Pages |
Abstract
More patients receiving panitumumab + FOLFOX4 versus FOLFOX4 had ⩾30% or ⩾20% TS at week 8; PFS and OS were also improved with panitumumab + FOLFOX4. The clinical value of achieving early TS in mCRC warrants further investigation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jean-Yves Douillard, Salvatore Siena, Marc Peeters, Reija Koukakis, Jan-Henrik Terwey, Josep Tabernero,